Company intelligence / Profile preview

Prexton Therapeutics

Plan-les-Ouates, Geneva, Switzerlandprextontherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Prexton Therapeutics was a Swiss biopharmaceutical company dedicated to developing innovative therapies for Parkinson's disease. The company specialized in positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGluR4), a target aimed at balancing signaling in the brain's basal ganglia. Its lead clinical candidate, foliglurax, was a first-in-class small molecule designed to treat motor symptoms and levodopa-induced dyskinesia. Founded in 2012 as a spin-off from Merck Serono, Prexton was part of a growing cluster of neurology-focused biotechs in Geneva. In 2018, the company was acquired by Lundbeck for up to €905 million to strengthen Lundbeck's position in movement disorders.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Merck Serono

Beyond the preview

Go deeper on Prexton Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prexton Therapeutics.